Entrectinib is FDA approved for:

• NTRK-positive solid tumors without a known resistance mutation; metastatic, or where surgical resection is likely to result in severe morbidity; and that have progressed following treatment or have no satisfactory alternative therapy
• ROS1-positive metastatic NSCLC

Entrectinib is not approved for use in ALK-positive NSCLC.

Reference:
U.S. Food & Drug Administration (FDA). Oncology (Cancer) / Hematologic Malignancies Approval Notifications. Reviewed June 20, 2023. Accessed June 20, 2023. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm